The results of PEARL (Registry of AngioJet use in the peripheral vascular system), a phase II multicentre registry, led by Robert Lookstein, chief of interventional radiology, Mount Sinai Medical Center, New York, USA, have suggested that rheolytic pharmacomechanical thrombectomy using combination therapy is fast and effective and can reduce treatment time for deep vein thrombosis from more than two days to less than 24 hours according to data presented at the Annual International Symposium on Endovascular Therapy (ISET).
Volcano announced on 1 February 2013 it has a new interactive educational tool to facilitate learning about IVUS-guided interventional procedures with its new Visions PV .035 Digital IVUS catheter. The new Aortic IVUS App for iPad, available on the Apple App Store, provides case examples with interactive education on the procedural workflow and image interpretation, and is intended for healthcare professionals involved in endovascular aortic procedures.
Treating abdominal aortic aneurysm patients in an outpatient setting is feasible, with 0% mortality in a series conducted in Switzerland, according to data presented at the Controversies & Updates in Vascular Surgery symposium (17–19 January 2013) in Paris, France. Mario Lachat, University Hospital Zurich, Switzerland, told delegates that this type of procedure saves hospital costs and can be used in up to 40% of EVAR patients.
AngioScore has announced the launch of its new 100mm length AngioSculpt PTA Scoring Balloon Catheters for the treatment of peripheral arterial disease (PAD) below the knee (BTK).
Gore has introduced the Gore DrySeal sheath with hydrophilic coating in Europe. The new Gore DrySeal Sheath allows for easier insertion into and removal from blood vessels during endovascular repair procedures. The device is designed to increase sheath lubricity with an advantage of minimizing particulation of the hydrophilic coating.
Covidien announced on 23 January 2013 CE mark approval for its EverFlex self-expanding peripheral stent with Entrust delivery system. The advanced stent delivery system, specifically engineered for optimal control, is designed to allow physicians to consistently place stents in the desired location with accuracy and ease. The product will be rolled out in Western Europe next month.
Cardiovascular Systems announced on 23 January 2013 CONFIRM study series data presented at the 2013 International Symposium on Endovascular Therapy (ISET). Results show that CSI’s minimally invasive orbital atherectomy system is an effective treatment for peripheral arterial disease.
Spectranetics announced on 24 January 2013 final results from the PATENT (Photo-ablation using the Turbo-Booster and Excimer laser for in-stent restenosis treatment) study evaluating the safety and efficacy of the Spectranetics peripheral laser atherectomy catheters for the treatment of in-stent restenosis in the femoropopliteal artery in the leg.
Medtronic has announced the CE mark and international launch of its Complete SE (self-expanding) vascular stent for use in the lower extremities – specifically, the superficial femoral arteries and proximal popliteal arteries. In the United States, the Complete SE stent is approved by the FDA only for use in the iliac arteries.
Endologix announced on 24 January 2013 achievement of the CE mark of the Nellix EndoVascular Aneurysm Sealing System for the treatment of patients with abdominal aortic aneurysms. Nellix is the first available endovascular aneurysm sealing (EVAS) system. EVAS with Nellix is an advanced treatment strategy designed to simplify endovascular abdominal aortic aneurysm procedures, treat a broad range of patients, and provide enhanced clinical outcomes. The Nellix system is not approved in the United States for either investigational use or commercial sale.
Los pacientes con las arterias de las piernas bloqueadas tienen menos probabilidades de sufrir complicaciones tras un procedimiento para abrir sus arterias si dejan de fumar y toman aspirina y estatinas para reducir el colesterol, indica un estudio reciente.
On 21 January 2013, TriVascular announced FDA approval of the Ovation Prime Abdominal Stent Graft System for the treatment of abdominal aortic aneurysms. Ovation Prime builds upon the strong clinical experience of TriVascular’s Ovation stent graft by improving delivery system attributes to further enhance ease of use. Delivered through a 14F (4.7mm) outer diameter catheter, Ovation Prime is the lowest profile commercially available system for endovascular aortic repair (EVAR).
Eurocor unveiled interim results of the ongoing Freeway Stent Study on 17 January 2013 at IROS (Interventionell Radiologische Olbert Symposium), Berlin, Germany. The study was presented during the Free Paper Session 2 by Josef Tacke, Klinikum Passau, Germany. The multicentre, open, prospective randomised trial investigates the prevention of restenosis by drug-eluting balloon dilatation (Freeway) after stenting with a nitinol stent versus dilatation with standard balloon angioplasty after stenting with a nitinol stent in the treatment of superficial femoral artery or popliteal artery lesions.
Las mujeres con un trastorno hormonal llamado síndrome de ovario poliquístico (SOP) y que usan píldoras anticonceptivas tienen el doble de riesgo de desarrollar coagulos sanguíneos que otras usuarias de la píldora.
AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, today announced the launch of its new 100 mm length AngioSculpt PTA Scoring Balloon Catheters for the treatment of peripheral artery disease (PAD) below the knee (BTK)
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos